Mariner
CCCC icon

Mariner’s C4 Therapeutics CCCC Stock Holding History

Mariner’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-127,517
Closed -$334K – 3572
2026
Q1 		$334K Sell
127,517
-533
-0.4% -$1.25K ﹤0.01% 2772
2025
Q4 		$245K Sell
128,050
-187
-0.1% -$443 ﹤0.01% 3018
2025
Q3 		$285K Sell
128,237
-4,528
-3% -$10.9K ﹤0.01% 2859
2025
Q2 		$190K Sell
132,765
-47,607
-26% -$69.2K ﹤0.01% 3069
2025
Q1 		$289K Buy
180,372
+12,397
+7% +$37K ﹤0.01% 2657
2024
Q4 		$605K Buy
167,975
+37,564
+29% +$187K ﹤0.01% 2028
2024
Q3 		$743K Buy
130,411
+2,532
+2% +$15.2K ﹤0.01% 1832
2024
Q2 		$591K Sell
127,879
-158
-0.1% -$942 ﹤0.01% 1926
2024
Q1 		$1.05M Hold
128,037
– – ﹤0.01% 1469
2023
Q4 		$723K Buy
128,037
+1,546
+1% +$3.52K ﹤0.01% 1674
2023
Q3 		$235K Sell
126,491
-15,317
-11% -$46.7K ﹤0.01% 2377
2023
Q2 		$390K Buy
141,808
+13,814
+11% +$44.4K ﹤0.01% 1922
2023
Q1 		$402K Sell
127,994
-93
-0.1% -$548 ﹤0.01% 1833
2022
Q4 		$756K Buy
128,087
+2,683
+2% +$22.2K ﹤0.01% 1381
2022
Q3 		$1.1M Sell
125,404
-175
-0.1% -$1.82K ﹤0.01% 1007
2022
Q2 		$947K Buy
125,579
+549
+0.4% +$4.83K ﹤0.01% 916
2022
Q1 		$3.03M Buy
+125,030
New +$3.04M 0.01% 615

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Mariner's CCCC Position: Q2 2026 in Review

Mariner sold out of C4 Therapeutics (CCCC) in Q2 2026, closing a stake of 127,517 shares — an estimated $334K sold.

Mariner first reported a position in CCCC in Q1 2022 and held it in 17 quarters. The position peaked at $3.03M in Q1 2022. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Mariner reported no remaining C4 Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Mariner sold 127,517 C4 Therapeutics shares in Q2 2026, an estimated $334K.
  • Mariner first reported a position in C4 Therapeutics in Q1 2022 and held it in 17 quarters.
  • Mariner's C4 Therapeutics position peaked at $3.03M in Q1 2022.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.